These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16699867)
21. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma. Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590 [TBL] [Abstract][Full Text] [Related]
22. [Hepatocellular carcinoma and liver transplantation]. Fehérvári I Orv Hetil; 2010 Aug; 151(32):1285-8. PubMed ID: 20656667 [TBL] [Abstract][Full Text] [Related]
23. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813 [TBL] [Abstract][Full Text] [Related]
24. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892 [TBL] [Abstract][Full Text] [Related]
25. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Toyoda H; Kumada T; Osaki Y; Oka H; Urano F; Kudo M; Matsunaga T Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1528-36. PubMed ID: 17162244 [TBL] [Abstract][Full Text] [Related]
26. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302 [TBL] [Abstract][Full Text] [Related]
27. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma. Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509 [TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma, a unique tumor with a lack of biomarkers. Debes JD; Carrera E; Mattos AZ; Prieto JE; Boonstra A; Ann Hepatol; 2019; 18(6):786-787. PubMed ID: 31494068 [TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507 [TBL] [Abstract][Full Text] [Related]
31. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627 [TBL] [Abstract][Full Text] [Related]
32. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment. Trojan J; Raedle J; Zeuzem S Digestion; 1998 Jul; 59 Suppl 2():72-4. PubMed ID: 9718428 [No Abstract] [Full Text] [Related]
34. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Sugimoto H; Takeda S; Inoue S; Kaneko T; Watanabe K; Nakao A Liver Int; 2003 Feb; 23(1):38-44. PubMed ID: 12640726 [TBL] [Abstract][Full Text] [Related]
35. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. Hakamada K; Kimura N; Miura T; Morohashi H; Ishido K; Nara M; Toyoki Y; Narumi S; Sasaki M World J Gastroenterol; 2008 Mar; 14(9):1370-7. PubMed ID: 18322950 [TBL] [Abstract][Full Text] [Related]
37. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. Masuda T; Beppu T; Horino K; Komori H; Hayashi H; Okabe H; Otao R; Horlad H; Ishiko T; Takamori H; Kikuchi K; Baba H J Surg Oncol; 2010 Oct; 102(5):490-6. PubMed ID: 19937994 [TBL] [Abstract][Full Text] [Related]
38. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807 [TBL] [Abstract][Full Text] [Related]
39. Predictors of Microvascular Invasion in Hepatocellular Carcinoma. Yamashita Y; Shirabe K; Aishima S; Maehara Y Dig Dis; 2015 Sep; 33(5):655-60. PubMed ID: 26398341 [TBL] [Abstract][Full Text] [Related]
40. Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. Mita Y; Aoyagi Y; Suda T; Asakura H J Hepatol; 2000 Jun; 32(6):946-54. PubMed ID: 10898315 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]